Niagen Bioscience, Inc. Net Assets
Niagen Bioscience, Inc. net assets. Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has net assets worth $82.53 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($106.59 Million) and total liabilities ($24.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NAGE net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $82.53 Million |
| % of Total Assets | 77.43% |
| Annual Growth Rate | 105.44% |
| 5-Year Change | 141.22% |
| 10-Year Change | 667.3% |
| Growth Volatility | 222555.36 |
Net Assets of Niagen Bioscience, Inc. (2007–2025)
Net assets of Niagen Bioscience, Inc. from 2007 to 2025. This chart illustrates how Niagen Bioscience, Inc.'s net assets have evolved over time, based on quarterly financial data. See Niagen Bioscience, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Niagen Bioscience, Inc. (2007–2025)
The table below shows the annual net assets of Niagen Bioscience, Inc. from 2007 to 2025. For live market cap and overall valuation, see market value of Niagen Bioscience, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $76.53 Million | +66.04% |
| 2024-12-31 | $46.09 Million | +61.98% |
| 2023-12-31 | $28.46 Million | -0.75% |
| 2022-12-31 | $28.67 Million | -9.63% |
| 2021-12-31 | $31.73 Million | +93.17% |
| 2020-12-31 | $16.42 Million | -19.67% |
| 2019-12-31 | $20.45 Million | -24.77% |
| 2018-12-31 | $27.18 Million | -49.52% |
| 2017-12-31 | $53.83 Million | +439.72% |
| 2016-12-31 | $9.97 Million | +89.10% |
| 2015-12-31 | $5.27 Million | +31.92% |
| 2014-12-31 | $4.00 Million | -29.43% |
| 2013-12-31 | $5.67 Million | +41.87% |
| 2012-12-31 | $3.99 Million | +55.91% |
| 2011-12-31 | $2.56 Million | -48.11% |
| 2010-12-31 | $4.94 Million | +371.26% |
| 2009-12-31 | $1.05 Million | -40.12% |
| 2008-12-31 | $1.75 Million | +971657.22% |
| 2007-12-31 | $180.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Niagen Bioscience, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16448818000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Niagen Bioscience, Inc. Net Assets Breakdown (December 2025)
Niagen Bioscience, Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $79.00K | 0.10% |
| Other Comprehensive Income | $-9.00K | -0.01% |
| Other Components | $240.99 Million | 314.89% |
| Total Equity | $76.53 Million | 100.00% |
Niagen Bioscience, Inc. Competitors by Market Cap
The table below lists competitors of Niagen Bioscience, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Provident Agro Tbk
JK:PALM
|
$188.06 Million |
|
ANGI Homeservices Inc
NASDAQ:ANGI
|
$188.08 Million |
|
Eureka Group Holdings Ltd
AU:EGH
|
$188.16 Million |
|
SOL-GEL TECHN. IS-10
F:4SG
|
$188.25 Million |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089
|
$187.92 Million |
|
Lotus Technology Inc.
NASDAQ:LOT
|
$187.89 Million |
|
Korea Asset In Trust Co Ltd
KO:123890
|
$187.83 Million |
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
$187.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Niagen Bioscience, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 46,094,000 to 76,533,000, a change of 30,439,000 (66.0%).
- Net income of 17,382,000 contributed positively to equity growth.
- Share repurchases of 251,000 reduced equity.
- Other comprehensive income decreased equity by 5,000.
- Other factors increased equity by 13,313,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $17.38 Million | +22.71% |
| Share Repurchases | $251.00K | -0.33% |
| Other Comprehensive Income | $-5.00K | -0.01% |
| Other Changes | $13.31 Million | +17.4% |
| Total Change | $- | 66.04% |
Book Value vs Market Value Analysis
This analysis compares Niagen Bioscience, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 70094.18x to 2.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.00 | $2.36 | x |
| 2008-12-31 | $0.19 | $2.36 | x |
| 2009-12-31 | $0.11 | $2.36 | x |
| 2010-12-31 | $0.31 | $2.36 | x |
| 2011-12-31 | $0.11 | $2.36 | x |
| 2012-12-31 | $0.12 | $2.36 | x |
| 2013-12-31 | $0.17 | $2.36 | x |
| 2014-12-31 | $0.11 | $2.36 | x |
| 2015-12-31 | $0.15 | $2.36 | x |
| 2016-12-31 | $0.27 | $2.36 | x |
| 2017-12-31 | $1.21 | $2.36 | x |
| 2018-12-31 | $0.49 | $2.36 | x |
| 2019-12-31 | $0.36 | $2.36 | x |
| 2020-12-31 | $0.27 | $2.36 | x |
| 2021-12-31 | $0.47 | $2.36 | x |
| 2022-12-31 | $0.41 | $2.36 | x |
| 2023-12-31 | $0.38 | $2.36 | x |
| 2024-12-31 | $0.58 | $2.36 | x |
| 2025-12-31 | $0.90 | $2.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Niagen Bioscience, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 22.71%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.43%
- • Asset Turnover: 1.22x
- • Equity Multiplier: 1.39x
- Recent ROE (22.71%) is above the historical average (-1210.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -21323.33% | 0.00% | 0.00x | 3.22x | $-38.40K |
| 2008 | -120.31% | -46.70% | 1.10x | 2.33x | $-2.28 Million |
| 2009 | -86.65% | -15.71% | 1.62x | 3.40x | $-1.01 Million |
| 2010 | -41.56% | -27.12% | 1.16x | 1.32x | $-2.55 Million |
| 2011 | -308.24% | -97.32% | 1.29x | 2.45x | $-8.15 Million |
| 2012 | -292.05% | -100.45% | 1.29x | 2.26x | $-12.06 Million |
| 2013 | -78.01% | -43.50% | 1.13x | 1.59x | $-4.99 Million |
| 2014 | -134.76% | -35.19% | 1.33x | 2.88x | $-5.79 Million |
| 2015 | -52.54% | -15.49% | 0.95x | 3.55x | $-3.30 Million |
| 2016 | -29.36% | -13.52% | 1.10x | 1.98x | $-3.93 Million |
| 2017 | -21.14% | -53.67% | 0.34x | 1.17x | $-16.76 Million |
| 2018 | -122.58% | -105.57% | 0.75x | 1.55x | $-36.03 Million |
| 2019 | -157.24% | -69.45% | 1.15x | 1.97x | $-34.19 Million |
| 2020 | -121.32% | -33.62% | 1.54x | 2.34x | $-21.57 Million |
| 2021 | -85.50% | -40.22% | 1.17x | 1.82x | $-30.30 Million |
| 2022 | -57.69% | -22.96% | 1.33x | 1.89x | $-19.41 Million |
| 2023 | -17.35% | -5.91% | 1.52x | 1.93x | $-7.78 Million |
| 2024 | 18.55% | 8.58% | 1.46x | 1.48x | $3.94 Million |
| 2025 | 22.71% | 13.43% | 1.22x | 1.39x | $9.73 Million |
Industry Comparison
This section compares Niagen Bioscience, Inc.'s net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $1,449,808,915
- Average return on equity (ROE) among peers: -77.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Niagen Bioscience, Inc. (NAGE) | $82.53 Million | -21323.33% | 0.29x | $187.96 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $199.86 Million | -2.89% | 0.00x | $4.86 Million |
| Agape ATP Corporation Common Stock (ATPC) | $-24.99K | 0.00% | 0.00x | $1.30 Million |
| B&G Foods Inc (BGS) | $785.66 Million | 13.93% | 2.87x | $192.18 Million |
| BioHarvest Sciences Inc. Common Stock (BHST) | $25.45 Million | -43.76% | 0.87x | $33.89 Million |
| BranchOut Food Inc. Common Stock (BOF) | $2.34 Million | -202.92% | 4.49x | $27.97 Million |
| Bellring Brands LLC (BRBR) | $-205.90 Million | 0.00% | 0.00x | $1.10 Billion |
| BRC Inc. (BRCC) | $-1.25 Million | 0.00% | 0.00x | $216.27 Million |
| BRF SA ADR (BRFS) | $13.64 Billion | 5.90% | 1.04x | $5.38 Billion |
| Bridgford Foods Corporation (BRID) | $50.80 Million | 17.13% | 0.49x | $47.83 Million |
| Borealis Foods Inc. (BRLS) | $4.64 Million | -566.46% | 12.96x | $23.82 Million |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulat… Read more